☆ 4.7 Letter

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al

ANNALS OF THE RHEUMATIC DISEASES (2023)

Journal

ANNALS OF THE RHEUMATIC DISEASES

Volume 82, Issue 5, Pages -

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/annrheumdis-2021-220134

Keywords

epidemiology; inflammation; vaccination; autoimmune diseases; COVID-19

Categories

Rheumatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination

Azam Safary, Kamal Esalatmanesh, Amir Taher Eftekharsadat, Mohammad -Reza Jafari Nakjavani, Alireza Khabbazi

Summary: Vaccination against COVID-19 is important for achieving herd immunity and controlling the pandemic. However, a small number of people may develop autoimmune rheumatic diseases (ARDs) as a rare adverse reaction to the vaccines. This study identifies individuals who developed de-novo ARDs after COVID-19 vaccination, with a higher prevalence among those who received the AstraZeneca vaccine. Prompt diagnosis and treatment can prevent irreversible organ damage.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Article Virology

The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination

Jerzy Swierkot, Marta Madej, Magdalena Szmyrka, Lucyna Korman, Renata Sokolik, Iga Andrasiak, Ewa Morgiel, Agata Sebastian

Summary: This study evaluated the prevalence of autoimmune antibodies before and after SARS-CoV-2 mRNA vaccination in healthcare professionals. The findings showed no significant increase in the prevalence of certain antibodies or autoimmune diseases after vaccination. However, there was an association between the severity of vaccine adverse events and ANA titre.

VIRUSES-BASEL (2022)

Add to Collection

Article Immunology

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph

Summary: This study aimed to determine the optimal time for COVID-19 vaccination in patients with immune-mediated dermatologic diseases (IMDD) who have been exposed to rituximab. The results showed that waiting for 9 months after rituximab treatment before vaccination maximizes the immunological benefits while avoiding unnecessary delay.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Rheumatology

Efficacy of COVID-19 vaccines in patients taking immunosuppressants

Chen Shen, Malcolm Risk, Elena Schiopu, Salim S. Hayek, Tiankai Xie, Lynn Holevinski, Cem Akin, Gary Freed, Lili Zhao

Summary: The study found that the mRNA-1273 and BNT162b2 vaccines are effective in individuals taking immunosuppressants. However, these individuals are still at higher risk of SARS-CoV-2 infection and COVID-19 hospitalization compared to the general vaccinated population. Booster doses are effective and crucial for individuals on immunosuppressants.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N. Albach, Jens Klotsche, Veronika Scholz, Lara Maria Jeworowski, Tatjana Schwarz, Alexander ten Hagen, Jan Zernicke, Victor Max Corman, Christian Drosten, Gerd-Ruediger Burmester, Robert Biesen

Summary: This study found that methotrexate (MTX) reduces the humoral immune response to COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD), and discontinuing MTX for at least 10 days significantly improves antibody response in patients over 60 years old.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Immunology

New-onset autoimmune phenomena post-COVID-19 vaccination

Yue Chen, Zhiwei Xu, Peng Wang, Xiao-Mei Li, Zong-Wen Shuai, Dong-Qing Ye, Hai-Feng Pan

Summary: Autoimmune manifestations have been reported in response to certain COVID-19 vaccines, but it is still unclear whether there is a causal relationship. These reports can help guide the clinical assessment and management of autoimmune manifestations after vaccination.

IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Insights into new-onset autoimmune diseases after COVID-19 vaccination

Ming Guo, Xiaoxiao Liu, Xiangmei Chen, Qinggang Li

Summary: COVID-19, caused by SARS-CoV-2, has resulted in more than 670 million infections and almost 7 million deaths globally. Omicron variant of SARS-CoV-2 has become dominant due to its high infectivity and immune evasion. COVID-19 vaccination may lead to new-onset autoimmune diseases, but the causal relationship is yet to be established. This review provides evidence of vaccination-induced autoimmunity and possible mechanisms, aiming to raise awareness about the potential risks while emphasizing the overall benefits of vaccination.

AUTOIMMUNITY REVIEWS (2023)

Add to Collection

Article Rheumatology

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Sebastian Eduardo Sattui, Jean W. Liew, Kevin Kennedy, Emily Sirotich, Michael Putman, Tarin T. Moni, Akpabio Akpabio, Deshire Alpizar-Rodriguez, Francis Berenbaum, Inita Bulina, Richard Conway, Aman Dev Singh, Eimear Duff, Karen L. Durrant, Tamer A. Gheita, Catherine L. Hill, Richard A. Howard, Bimba F. Hoyer, Evelyn Hsieh, Lina El Kibbi, Adam Kilian, Alfred Hyoungju Kim, David F. L. Liew, Chieh Lo, Bruce Miller, Serena Mingolla, Michal Nudel, Candace A. Palmerlee, Jasvinder A. Singh, Namrata Singh, Manuel Francisco Ugarte-Gil, John Wallace, Kristen J. Young, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro M. Machado, Philip C. Robinson, Paul Sufka, Zachary S. Wallace, Jinoos Yazdany, Carly Harrison, Maggie Larche, Mitchell Levine, Gary Foster, Lehana Thabane, Lisa G. Rider, Jonathan S. Hausmann, Julia F. Simard, Jeffrey A. Sparks

Summary: Among adults with systemic rheumatic disease who received COVID-19 vaccination, most patients were willing to temporarily discontinue disease-modifying antirheumatic drugs (DMARDs) to improve vaccine efficacy. Patient-reported adverse events were typical of those reported in the general population, and the relatively low frequency of rheumatic disease flare requiring medication changes was reassuring.

RMD OPEN (2021)

Add to Collection

Review Immunology

COVID-19 Vaccination Hesitancy in Autoimmune Disease Patients: Policy Action and Ethical Considerations

Nardeen Shafik, Jennifer E. Akpo, Kristie C. Waterfield, William A. Mase

Summary: As COVID-19 vaccination guidelines were issued, each state and clinical provider had different implementation and education policies for high-risk populations, including people with autoimmune diseases. However, the adherence to these policies varied, affecting vaccine hesitancy and low vaccination rates. It is important to address this issue and provide tailored vaccination campaigns for this vulnerable population.

VACCINES (2023)

Add to Collection

Review Immunology

Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo

Laura Macca, Lucia Peterle, Manuela Ceccarelli, Ylenia Ingrasciotta, Giuseppe Nunnari, Claudio Guarneri

Summary: An increasing number of cases of new-onset or worsening vitiligo have been reported following COVID-19 vaccination, suggesting a potential autoimmune trigger.

VACCINES (2022)

Add to Collection

Review Immunology

Autoimmune hepatitis after COVID-19 vaccination

Han Zheng, Ting Zhang, Yiyao Xu, Xin Lu, Xinting Sang

Summary: Cases of autoimmune hepatitis (AIH) after COVID-19 vaccination have been reported, suggesting a potential autoimmune reaction. This study summarizes 27 cases of AIH, providing emerging evidence of such autoimmune phenomena in response to COVID-19 vaccines. Factors such as molecular mimicry, adjuvants, epitope spreading, and bystander activation may contribute to the development of AIH. Corticosteroids appear to be effective in treating post-vaccination AIH, but further research is needed to determine the exact mechanism and causality.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Control of COVID-19 Outbreaks under Stochastic Community Dynamics, Bimodality, or Limited Vaccination

Bjorn Goldenbogen, Stephan O. Adler, Oliver Bodeit, Judith A. H. Wodke, Ximena Escalera-Fanjul, Aviv Korman, Maria Krantz, Lasse Bonn, Rafael Moran-Torres, Johanna E. L. Haffner, Maxim Karnetzki, Ivo Maintz, Lisa Mallis, Hannah Prawitz, Patrick S. Segelitz, Martin Seeger, Rune Linding, Edda Klipp

Summary: This article analyzes the effects of nonpharmaceutical interventions (NPIs) and vaccination strategies on COVID-19 epidemiology using a detailed community-specific agent-based model (ABM). The authors find that the threshold for population immunity depends on the vaccination strategy, with prioritizing highly interactive people reducing the risk of infection and prioritizing the elderly minimizing fatalities. The article also highlights the importance of adaptive combination of NPIs and targeted vaccination in controlling COVID-19 outbreaks.

ADVANCED SCIENCE (2022)

Add to Collection

Article Rheumatology

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

Felix Kartnig, Daniel Mrak, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Goeschl, Nikolaus Hommer, Margareta Mayer, Philipp Hofer, Thomas Hummel, Thomas Deimel, Irina Gessl, Antonia Puchner, Andreas Kerschbaumer, Renate Thalhammer, Alessandra Handisurya, Renate Kain, Stefan Winkler, Josef S. Smolen, Karin Stiasny, Thomas Perkmann, Helmuth Haslacher, Judith H. Aberle, Daniel Aletaha, Leonhard X. Heinz, Daniela Sieghart, Michael Bonelli

Summary: This clinical trial evaluated the immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs). The results showed that the third vaccination had good immunogenicity and safety in these patients, but the effects of immunomodulatory therapy should be considered.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis

R. Naveen, Ioannis Parodis, Mrudula Joshi, Parikshit Sen, Julius Lindblom, Vishwesh Agarwal, James B. Lilleker, Ai Lyn Tan, Arvind Nune, Samuel Katsuyuki Shinjo, Babur Salim, Nelly Ziade, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Miguel A. Saavedra, Jessica Day, Ashima Makol, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, Elena Nikiphorou

Summary: The COVAD study aimed to assess short-term adverse events (AEs) related to COVID-19 vaccination in rheumatoid arthritis (RA) patients. The study found that all COVID-19 vaccines were well tolerated in RA patients, with similar rates of AEs compared to healthy controls.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld, Martin Schafer, Milena A. Gianfrancesco, Saskia Lawson-Tovey, Jean W. Liew, Lotta Ljung, Elsa F. Mateus, Christophe Richez, Maria J. Santos, Gabriela Schmajuk, Carlo A. Scire, Emily Sirotich, Jeffrey A. Sparks, Paul Sufka, Thierry Thomas, Laura Trupin, Zachary S. Wallace, Sarah Al-Adely, Javier Bachiller-Corral, Suleman Bhana, Patrice Cacoub, Loreto Carmona, Ruth Costello, Wendy Costello, Laure Gossec, Rebecca Grainger, Eric Hachulla, Rebecca Hasseli, Jonathan S. Hausmann, Kimme L. Hyrich, Zara Izadi, Lindsay Jacobsohn, Patricia Katz, Lianne Kearsley-Fleet, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group

Jose B. Nergon, Maria A. Lopez-Olivo, Loreto Carmona, Robin Christensen, Francesca Ingegnoli, Natalia Zamora, Jorge I. Gamez-Nava, Laura Gonzalez-Lopez, Vibeke Strand, Niti Goel, Tiffany Westrich-Robertson, Maria E. Suarez-Almazor

Summary: This study aimed to identify patient-centered domains with long-term relevance to people with rheumatoid arthritis (RA). Semi-structured individual cognitive interviews were conducted with RA patients from five different countries. Six main themes were identified, including living with symptoms and functional limitations, lack of participation, partner and family issues, risk of damage to vital organs, coping strategies, and healthcare concerns. These domains are seldom measured in longitudinal registries and should be considered in patient-centered longitudinal studies.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Add to Collection

Article Rheumatology

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gomez-Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelka, Dan C. Nordstrom, Nevsun Inanc, Catalin Codreanu, Kimme L. Hyrich, Denis Choquette, Anja Strangfeld, Burkhard F. Leeb, Ziga Rotar, Ana Rodrigues, Eirik Klami Kristianslund, Tore K. Kvien, Ori Elkayam, Galina Lukina, Sytske Anne Bergstra, Axel Finckh, Delphine Sophie Courvoisier

Summary: The objective of this study was to compare the effectiveness of cycling Janus kinase inhibitors (JAKi) with switching to biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA). The results showed that both strategies had similar observed drug retention rates after 2 years, but cycling JAKi was associated with higher retention after adjusting for confounders. It was also found that if the first JAKi was discontinued due to an adverse event (AE), it was more likely that the second JAKi would also be stopped due to an AE. Improvement in Clinical Disease Activity Index (CDAI) over time was similar in both strategies.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Continuing specialist care into adulthood in young people with juvenile idiopathic arthritis: a retrospective cohort study using electronic health records in England

Ruth E. Costello, Lianne Kearsley-Fleet, Janet E. McDonagh, Kimme Hyrich, Jenny H. Humphreys

Summary: This study found that two-thirds of young people with JIA continue to receive specialist care beyond age 18. Older age at diagnosis, female gender, less deprivation, and a childhood diagnosis of uveitis were associated with continuing specialist care.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status

Sinead Maguire, Samar Al-Emadi, Paula Alba, Mathia Cecilia Aguiar, Talal Al Lawati, Gelsomina Alle, Bonnie Bermas, Suleman Bhana, Anic Branimir, Inita Bulina, Megan Clowse, Karina Cogo, Iris Colunga, Claire Cook, Karen J. Cortez, Kathryn Dao, Milena Gianfrancesco, Monique Gore-Massey, Laure Gossec, Rebecca Grainger, Jonathon Hausman, Tiffany Y. T. Hsu, Kimme Hyrich, Carolina Isnardi, Yumeko Kawano, Rachael Kilding, Daria A. Kusevich, Saskia Lawson-Tovey, Jean Liew, Eoghan McCarthy, Anna Montgumery, Sebastian Moyano, Noreen Nasir, Ivan Padjen, Charalampos Papagoras, Naomi J. Patel, Mariana Pera, Cecilia Pisoni, Guillermo Pons-Estel, Antonio L. Quiambao, Rosana Quintana, Eric Ruderman, Sebastian Sattui, Veronica Savio, Savino Sciascia, Marieta Sencarova, Rosa Serrano Morales, Faizah Siddique, Emily Sirotich, Jeffrey Sparks, Anja Strangfeld, Paul Sufka, Helen Tanner, Yohana Tissera, Zachary Wallace, Marina L. Werner, Leanna Wise, Angus B. Worthing, JoAnn Zell, Julija Zepa, Pedro M. Machado, Jinoos Yazdany, Philip Robinson, Richard Conway

Summary: This study describes obstetric outcomes based on COVID-19 vaccination status in pregnant women with rheumatic and musculoskeletal diseases (RMDs). The results show that unvaccinated pregnant women have a higher rate of preterm births, and the need for COVID-19 pharmacological treatment is rare regardless of vaccination status.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis

Stefan Siebert, Frank Behrens, Ennio Lubrano, Nicolas Martin, Mohamed Sharaf, Christine Contre, Elke Theander, Ruben Queiro, Miriam Zimmermann, Laure Gossec

Summary: This study aims to collect data on the long-term clinical practice of using guselkumab or interleukin-17 inhibitors for the treatment of PsA to understand drug persistence, effectiveness, and long-term safety. Data will be collected through electronic patient-reported outcomes and physician-completed assessments, along with safety data. The study will last for 36 months with an additional 24-week observation period.

RHEUMATOLOGY AND THERAPY (2023)

Add to Collection

Review Rheumatology

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce

Gabriele De Marco, Alen Zabotti, Xenofon Baraliakos, Annamaria Iagnocco, Daniel Aletaha, Paulo Gisondi, Jenny Emmel, Josef S. Smolen, Dennis G. McGonagle, Laure Gossec

Summary: A systematic literature review found that patients with psoriasis who later developed psoriatic arthritis often experienced joint pain and functional limitations. Clinical and imaging characteristics can serve as indicators for predicting the development of psoriatic arthritis. Early psoriatic arthritis is predominantly oligoarticular.

RMD OPEN (2023)

Add to Collection

Article Rheumatology

Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies

Teresa A. Simon, Lixian Dong, Samy Suissa, Kaleb Michaud, Sofia Pedro, Marc Hochberg, Maarten Boers, Johan Askling, Thomas Frisell, Anja Strangfeld, Yvette Meissner, Vadim Khaychuk, Alyssa Dominique, Michael A. Maldonado

Summary: This study evaluated the risk of non-melanoma skin cancer associated with abatacept treatment for rheumatoid arthritis. The results suggest a potential increase in NMSC risk with abatacept use compared to conventional synthetic disease-modifying antirheumatic drugs.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Bimekizumab treatment in biologic DMARD-na & iuml;ve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Christopher T. Ritchlin, Laura C. Coates, Iain B. Mcinnes, Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B. M. Landewe

Summary: The long-term efficacy and safety of Bimekizumab (BKZ) in patients with psoriatic arthritis (PsA) was evaluated. The results showed that the efficacy of BKZ was sustained from Week 16 to Week 52, and patients who switched to BKZ treatment demonstrated similar efficacy to those who received BKZ continuously. BKZ treatment was well tolerated without any new safety signals.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith

Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.